ArticleBMC cancer2021
Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods.
Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis.Health technology assessment (Winchester, England) · 2023Pooled it
- Effect of coronavirus disease 2019 on diagnosis and treatment of hepatocellular carcinoma: a systematic review.Exploration of targeted anti-tumor therapy · 2023Pooled it
- Article
- Comment on "Stage‑specific impact of portal hypertension on outcomes after liver resection in hepatocellular carcinoma".Hepatology international · 2026Article
- Identification and validation of an explainable machine learning model for hepatocellular carcinoma at high risk: a retrospective multicenter cohort study.International journal of surgery (London, England) · 2026Article
- Construction and Validation of a Predictive Model for Post-TACE Recurrence Risk in Hepatocellular Carcinoma: A Retrospective Cohort Study.Journal of hepatocellular carcinoma · 2026Article
- Analysis of risk factors for early mortality following hepatectomy in hepatocellular carcinoma patients.BMC surgery · 2025Article
- Pre- and postoperative predictors of extrahepatic recurrence after curative resection for hepatocellular carcinoma.BMC cancer · 2025Article
- Prognostic Determinants and Treatment Strategies Associated with Long-Term Survival in Early-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study.Journal of hepatocellular carcinoma · 2025Article
- Article
- Heavy smoking increases early mortality risk in patients with hepatocellular carcinoma after curative treatment.Journal of liver cancer · 2024Article
- Development and Validation of a Nomogram for Patients Undergoing Transarterial Chemoembolization for Recurrent Hepatocellular Carcinoma After Hepatectomy.Journal of hepatocellular carcinoma · 2024Article
- The impact of tumor burden score on prognosis in patients after radical resection of hepatocellular carcinoma: a single-center retrospective study.Frontiers in oncology · 2024Article
- Recent advances in recurrent hepatocellular carcinoma therapy.World journal of hepatology · 2023Review
- Sex Differences in the Impact of Metabolic Dysfunction-associated Fatty Liver Disease on the of Patients with Hepatocellular Carcinoma After Radical Resection.Journal of Cancer · 2023Article
- Predictors of Hepatocellular Carcinoma Early Recurrence in Patients Treated with Surgical Resection or Ablation Treatment: A Single-Center Experience.Diagnostics (Basel, Switzerland) · 2022Article
- Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis.Annals of surgical oncology · 2022Article
- Transarterial Chemoembolization Combined With Radiofrequency Ablation Versus Hepatectomy for Hepatocellular Carcinoma: A Meta-Analysis.Frontiers in surgery · 2022Review
- Clinical Nursing Paths Benefit Patient Outcomes Undergoing Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe quantified the elusive effects of putative factors on the clinical course of early hepatocellular carcinoma (HCC) after primary surgical or nonsurgical curative treatment.
methodsPatients with newly diagnosed early HCC who received surgical resection (SR) or percutaneous radiofrequency ablation (RFA) with or without transcatheter arterial chemoembolization (TACE) from January 2003 to December 2016 were enrolled. The cumulative overall survival (OS) and disease-free survival (DFS) rates were compared. A polytomous logistic regression was used to estimate factors for early and late recurrence. Independent predictors of OS were identified using Cox proportional hazard regression.
resultsOne hundred twenty-five patients underwent SR, and 176 patients underwent RFA, of whom 72 were treated with TACE followed by RFA. Neither match analysis based on propensity score nor multiple adjustment regression yielded a significant difference in DFS and OS between the two groups. Multivariate analysis showed high AFP (> 20 ng/mL), and multinodularity significantly increased risk of early recurrence (< 1 year). In contrast, hepatitis B virus, hepatitis C virus and multinodularity were significantly associated with late recurrence (> 1 year). Multivariate Cox regression with recurrent events as time-varying covariates identified older age (HR = 1.55, 95% CI:1.01-2.36), clinically significant portal hypertension (CSPH) (HR = 1.97, 95% CI:1.26-3.08), early recurrence (HR = 6.62, 95% CI:3.79-11.6) and late recurrence (HR = 3.75, 95% CI:1.99-7.08) as independent risk factors of mortality. A simple risk score showed fair calibration and discrimination in early HCC patients after primary curative treatment. In the Barcelona Clinic Liver Cancer (BCLC) stage A subgroup, SR significantly improved DFS compared to RFA with or without TACE.
conclusionHost and tumor factors rather than the initial treatment modalities determine the outcomes of early HCC after primary curative treatment. Statistical models based on recurrence types can predict early HCC prognosis but further external validation is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.